Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Shandong Weigao Blood Purification Products Co Days Payable?
Shandong Weigao Blood Purification Products CoSHSE:603014 -6.07%38 Days Payable is 88.86 as of Mar. 2026, which is 19% below its 10-year median of 110.10. GuruFocus rates SHSE:603014 with a GF Score™ of 38/100. The stock has 3 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Shandong Weigao Blood Purification Products Co ranks better than 59.5% on this metric.
SHSE:603014's Days Payable is ranked better than 59.5% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs SHSE:603014: 86.06
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Weigao Blood Purification Products Co Days Payable Chart
Shandong Weigao Blood Purification Products Co Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Weigao Blood Purification Products Co Days Payable vs Medical Devices & Instruments Industry
Shandong Weigao Blood Purification Products Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Weigao Blood Purification Products Co (SHSE:603014) has a Days Payable of 88.86 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Shandong Weigao Blood Purification Products Co and its competitors. This is 19% below median its historical median of 110.10. Over the past decade, Shandong Weigao Blood Purification Products Co's Days Payable has ranged from 73.51 to 130.55. According to the industry distribution chart, Shandong Weigao Blood Purification Products Co ranks #322 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 40.5%.
Is Shandong Weigao Blood Purification Products Co's Days Payable too high?
Shandong Weigao Blood Purification Products Co's current Days Payable of 88.86 is 19% below median its 10-year median of 110.10. Over the past 10 years, this metric has ranged from a low of 73.51 to a high of 130.55. The Medical Devices & Instruments industry median Days Payable is 67.87. Shandong Weigao Blood Purification Products Co's value of 88.86 is 30.9% above this industry median. Based on the distribution chart, Shandong Weigao Blood Purification Products Co ranks #322 out of 795 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Shandong Weigao Blood Purification Products Co has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Shandong Weigao Blood Purification Products Co's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shandong Weigao Blood Purification Products Co ranks #322 out of 795 companies for Days Payable. This puts Shandong Weigao Blood Purification Products Co in the upper half of its industry. The industry median Days Payable is 67.87. Shandong Weigao Blood Purification Products Co's value of 88.86 is 30.9% above this benchmark. Historically, Shandong Weigao Blood Purification Products Co's own Days Payable has ranged from 73.51 to 130.55 over the past decade. While the company's 10-year median is 110.10 vs. the industry median of 67.87, Shandong Weigao Blood Purification Products Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shandong Weigao Blood Purification Products Co's current Days Payable of 88.86 is 30.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Shandong Weigao Blood Purification Products Co and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shandong Weigao Blood Purification Products Co's current Days Payable is 88.86, which is 19% below median its own 10-year median of 110.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Weigao Blood Purification Products Co stock overvalued right now?
Shandong Weigao Blood Purification Products Co (SHSE:603014) has a current Days Payable of 88.86. The current Days Payable is 88.86, which is 19% below median its 10-year median of 110.10 and 30.9% above the Medical Devices & Instruments industry median of 67.87. Shandong Weigao Blood Purification Products Co's overall GF Score™ is 38/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Shandong Weigao Blood Purification Products Co (SHSE:603014), the current Days Payable is 88.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shandong Weigao Blood Purification Products Co Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603014 has been successfully added to your 
